{"id":2482,"date":"2017-11-13T12:45:10","date_gmt":"2017-11-13T07:15:10","guid":{"rendered":"https:\/\/www.lalpathlabs.com\/blog\/?p=2482"},"modified":"2023-10-12T17:41:00","modified_gmt":"2023-10-12T12:11:00","slug":"liquid-biopsy","status":"publish","type":"post","link":"https:\/\/www.lalpathlabs.com\/blog\/liquid-biopsy\/","title":{"rendered":"Liquid Biopsy cfDNA, EGFR"},"content":{"rendered":"

\"liquid<\/p>\n

Liquid Biopsy<\/h2>\n\n\n\n\n\n\n\n\n
Test Name\u00a0<\/strong><\/td>\nLIQUID BIOPSY, cfDNA, EGFR<\/strong><\/td>\n<\/tr>\n
Clinical Utility<\/td>\n\u2022 Simple non-invasive blood draw.
\n\u2022 Not dependent on availability of tissue sample.
\n\u2022 Utilizes circulating cell-free DNA (cfDNA<\/a><\/span>) to provide comprehensive tumor mutational. profle.
\n\u2022 This is an in-house developed test useful. for the detection of exon 19 deletion (p.E746_A750deletion), Exon 20 point mutation (T790M) and Exon 21 point mutation (L858R).<\/td>\n<\/tr>\n
Patient Selection<\/td>\nPatients with limited traditional. cancer therapy options:
\n\u2022 Metastatic Cancer
\n\u2022 Refractory or resistant cancer<\/td>\n<\/tr>\n
Technology<\/td>\nDigital. Droplet PCR<\/td>\n<\/tr>\n
TAT<\/td>\nMon \/ Thu 9 am; Report Fri \/ Tue<\/td>\n<\/tr>\n
Specimen<\/td>\n10 mL Whole blood in 1 Streck tube.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparison between tissue biopsy & liquid biopsy<\/h3>\n\n\n\n\n\n\n\n\n\n
Tissue Biopsy\u00a0<\/strong><\/td>\nLiquid Biopsy<\/strong><\/td>\n<\/tr>\n
Lack of tumor heterogeneity<\/td>\nRepresentation of intra-tumoral complexity<\/td>\n<\/tr>\n
Not an option in severely ill patients<\/td>\nCan be a substitute for primary biopsy in severely ill patients<\/td>\n<\/tr>\n
No periodic monitoring for progression\/ recurrence<\/td>\nDynamic monitoring of molecular changes for progression\/recurrence<\/td>\n<\/tr>\n
Obtained by surgery, an expensive procedure. Not easily obtained<\/td>\nBody fluid\/blood is collected by a simple inexpensive procedure. Easily obtained<\/td>\n<\/tr>\n
Some pain and risk involved<\/td>\nMinimal pain and risk involved<\/td>\n<\/tr>\n
Invasive and uncomfortable (possibility of clinical complications)<\/td>\nMinimally invasive<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

When to use Liquid Biopsy?<\/span><\/h4>\n

\u2022 Patients under treatment to monitor therapy response and drug resistance
\n\u2022 Patients whose tumor is inaccessible
\n\u2022 Patients in remission for monitoring cancer recurrence
\n\u2022 Patients diagnosed with cancer for molecular profiling and therapy match
\n\u2022 Patients who have failed other treatments
\n\u2022 Patients with metastatic cancer<\/p>\n